Synaptogenix Inc (SNPX)

[Android 2-73]

"Bryostatin by Neurotrope (OTCQB:NTRPD) downregulates protein kinase C alpha and protein kinase C alpha is the linchpin in the initial production of inflammation and oxidation in Alzheimer's disease (bryostatin's effect, protein kinase C alpha). However, due to damage to upstream receptors in most people with Alzheimer's disease, protein kinase C alpha activity decreases as the disease progresses (study). So it is not likely that bryostatin can be used to help most people at least not past a certain stage."

This would be my concern. Since NTRP is testing in mide to late stage patients, i'm less confident in success. If it was early stages, i'd by buying here. i'll wait for data to invest here.

Link to Article